Kiromic Biopharma, Inc. Shareholder Notificaiton: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Kiromic Biopharma, Inc. (KRBP)
If you would like more information about Kiromic Biopharma Inc.'s misconduct, click here .
- If you would like more information about Kiromic Biopharma Inc.'s misconduct, click here .
- Rather than disclosing this information, Kiromic represented that clinical testing was expected to proceed in the third quarter of 2021.
- However, clinical testing did not proceed in the third quarter 2021, nor was it likely given the FDA's imposition of a clinical hold.
- A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.